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Abstract Intercalation of drugs in the platelet membrane
affects phospholipid-requiring enzymatic processes accord-
ing to the drugs’ intercalation capability. We investigated
effects of Promethazine, Citalopram, Ziprasidone, Risper-
idone, and Diazepam on phospholipase A2 (PLA2) and
polyphosphoinositide (PPI) metabolism in thrombin-
stimulated human platelets. We also examined effects of
the drugs on monolayers of glycerophospholipids using the
Langmuir technique. Diazepam did not influence PLA2
activity, had no effects on PPI cycle, and caused no change
in mean molecular area of phospholipid monolayers. The
remaining psychotropic drugs affected these parameters in
different ways and levels of potency suggesting that they
act by being intercalated between the molecules of adjacent
membrane phospholipids, thus causing changes in substrate
availability for phospholipid-hydrolyzing enzymes (PLA2
and Phospholipase C). We show that several psychotropic
drugs can also have other cellular effects than receptor
antagonism. These effects may be implicated in the
psychotropic effects of the drugs and/or their side effects.
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AA Arachidonic acid
(BDR)s (Benzodiazepine receptor)s
CTM Citalopram
CPZ Chlorpromazine
DMSO Dimethylsulfoxide
DPPC 1,2-Dipalmitoyl phosphatidylcholine
DPPS 1,2-Dipalmitoyl phosphatidylserine
DZP Diazepam
GABAA Gamma amino butyric acid
GFP Gel-filtered platelets
PRZ Promethazine
mma Mean molecular area (in Å
2)
MLC Myosin light chain
PC Phosphatidylcholine
PA Phosphatidic acid
PI Phosphatidylinositol
PIP Phosphatidyl-4-phosphate
PIP2 Phosphatidylinositol-4,5-bisphosphate
PS Phosphatidylserine
PPI Polyphosphoinositide
PLA2 Phospholipase A2
PLC Phospholipase C
PBPS Porcine brain phosphatidyl serine
PCP Prochlorperazine
Π Surface pressure (in mN/m)
RSP Risperidone
SSRI Selective serotonin re-uptake inhibitor
TFP Trifluoperazine
ZIP Ziprasidone
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The treatment of psychiatric diseases presents a great
challenge today, where the heaviest burden lies upon the
psychiatrist who has to choose the proper medication and
dosage for treatment of the different disorders, which have
a very broad spectrum. In order to find the optimal drug
with a very selective action on neurons, and at the same
time having minimal side effects on other systems in the
human body, it is essential to understand the pharmacology
and pharmacokinetics of individual drugs. To study these
two vital parameters, we have to gain knowledge of their
action at the cellular level. They initially bind to certain
receptors directly or by modification of receptor-mediated
action through intercalation into the lipid bilayer of neurons
or possibly a combination of both. Human platelets have
long been thought to lack D2 receptors [57], which are the
primary targets for antipsychotic drugs; however, very
recently, [60] reported that human platelets contain D2-like
receptors that mediate the potentiation of ADP-induced
aggregation. Human platelets have also other receptor types
like H1 [24], which is the target for Promethazine. They
have also alpha-2 and serotonin receptors, which are targets
for Ziprasidone [52] and other atypical antipsychotic drugs
[62].
Human platelets may serve as a supplementary diagnos-
tic probe to provide information on psychiatric diseases like
schizophrenia [15, 18, 77, 80]. In this study, we have used
human platelets to study the effects of five drugs on
biological phenomena: PLA2 metabolism, PPI cycle in
thrombin-stimulated human platelets. The drugs we have
chosen in this work are applied clinically to treat the most
common ailments which result in morbidity in psychiatric
health care, i.e., the triad of anxiety (Diazepam, Prometha-
zine), depression (Citalopram), and psychosis (Ziprasidone,
Risperidone).
Benzodiazepine receptors (BDRs) are classified into
central (two globular subunits of 200 and 400 kDa) [64]a n d
peripheral (two subunits of 18 and 30 kDa) classes [74].
Human platelets possess peripheral BDRs [47, 48]. Periph-
eral BDRs that are localized in the mitochondrial outer
membrane regulate steroid biosynthesis [41, 42] and mediate
inhibition of mitochondrial respiratory control [27, 51].
A brief introduction to the drugs (for their chemical
structures see Scheme 1) used in the study is given below:
Diazepam (DZP) is a benzodiazepine preparation, has a
very broad scale of clinical application, varying from
treatment of anxiety, insomnia, epilepsy, catatonic schizo-
phrenia [32], drug-induced tardive dyskinesia (e.g., first-
generation neuroleptics) [38] to its use in a rare disability as
a palliative measure in Stiff Person syndrome [28]. It
should not be recommended for long-term therapy because
of the development of pharmacological dependency.
Citalopram is an antidepressant, which belongs to a
group of selective serotonin re-uptake inhibitors (SSRI). Its
main clinical use is in the treatment of depression, but it
also has other applications such as treatment of painful
diabetic neuropathy [20, 65], premature ejaculation [4], and
poststroke pathological crying [2]. Escitalopram, which is a
steric isomer of citalopram, having the same chemical
structure, exhibits antiplatelet activity [3]. Citalopram is a
calmodulin antagonist [34].
Promethazine is a phenothiazine derivative of the first-
generation H1 receptor antagonists, used mainly as a
hypnotic, as an anti-emetic, in the treatment of hyperemesis
gravidarum [63], and as a preoperative medicine to
counteract post-narcotic nausea [75], an antipruritic, and
in a wide range of allergic situations (like allergic rhinitis,
hay fever). It has an inhibitory effect on platelet aggregation
induced by collagen, thrombin, or arachidonic acid (AA)
[37]. Similar to other phenothiazines, promethazine antag-
onizes calmodulin activities [45].
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Scheme 1 Chemical structures
of the drugs used in this work
90 J Chem Biol (2009) 2:89–103Risperidone is an atypical antipsychotic for treatment of
schizophrenia. It contains the functional group of benzisox-
azole and piperidine as part of its molecular structure.
It is a strong D2 receptor blocker [31], it also acts as a
5HT2A antagonist [79]. It reduces platelet aggregation by
different biological mechanisms [5, 13, 15].
Ziprasidone is an atypical antipsychotic, used mainly to
treat schizophrenia [68]; it has also received approval for
treatment of acute manic depressive psychosis [22, 78] and
has a high affinity for dopamine, serotonin, and α-
adrenergic receptors and a medium affinity for histamine
receptors [52]. Antagonism at both histaminic and α-
adrenergic receptors explains some of its side effects such
as sedation and orthostasis [55].
In the present work, we have investigated the effects of
these drugs on PPI metabolism and PLA2 activity in
thrombin-stimulated human platelets (intact biological sys-
tem in vitro). We have also employed the Langmuir
monolayer technique to examine the surface pressure/mean
molecular area (mma) isotherms of acidic and neutral
glycerophospholipids as in our two previous studies [53,
54]. We have previously demonstrated widely varying effects
of other psychotropic drugs on PPI metabolism [53]a n d
PLA2 activity and MLC phosphorylation [54] in such
stimulated platelets. Since these drugs greatly increased the
mean molecular area of phosphatidylserine monolayers [53,
54], we suggested that these effects could also be a result of
intercalation of these drugs in the inner leaflet of the plasma
membrane occurring in a receptor-unrelated fashion. The aim
of this work was to establish whether or not psychotropic
drugs exert their actions in similar ways at the cellular level.
Materials and methods
Chemicals
Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoyl-
phosphatidylserine (DPPS) were from Avanti Polar Lipids
(Alabaster, AL, USA); 20 µl (1 mg/ml) of these lipids were
used to make lipid monolayers in air/liquid interface by
applying the Langmuir apparatus.
Promethazine (PRZ) was obtained from Rhone-Poulec
Pharma Norden (Denmark). Diazepam (DZP) was from
Sigma (St. Louis, MO, USA). Citalopram (CTM) was from
Lundbeck (Denmark). Ziprasidone (ZIP) was from Pfizer.
Risperidone (RSP) was from (Janssen-Cilag).
Promethazine and CTM were dissolved in 0.15 M NaCl,
the stock solutions were stored in the dark at −20°C, and
dilutions were made with 0.15 M NaCl just before use.
Diazepam, RSP, and ZIP were dissolved in DMSO to
prepare the stock solutions and stored in the dark at –20°C.
Dilutions were made with 0.15 M NaCl just prior to use.
[
32P] Pi as (H3
32PO4), specific activity as (P) 285.6 Ci/mg
was from Perkin-Elmer Life and Analytical Science (Boston,
MA, USA). Thrombin (bovine) was from Parke-Davis
(Scarborough, ON, Canada) and stored in small portions of
100 U/ml 0.15 M NaCl at –20°C; appropriate dilutions in
0.15 M NaCl were made immediately before each experi-
ment, and the remaining stock portion was discarded.
[5, 6, 8, 9, 11, 12, 14, 15-
3H]Arachidonic acid (code
TRK508, 211 Ci/mmol) in toluene was from Amersham-
Pharmacia Biotech (Buckinghamshire, England).
Langmuir apparatus
The instrument used is based on a trough where the area of
monolayerattheair/waterinterfacecanbemodulated.AKSV
Minitrough (Helsinki, Finland) of dimensions 75 (width)×
364 (length)×5 (height) mm which is coated with (PTFE)
Poly Tetra Fluoro Ethylene, a highly hydrophobic and inert
material. In control experiments, the trough was filled with
Milli-Q water, containing appropriate amounts of NaCl or
DMSO as drug solvents, according to solubility of the drugs
used.Theexperimentswereperformedwitheither1or10µM
of drug solution. After the liquid/air interface has been
cleaned, the film-forming lipid molecules could be spread on
the surface.A 20-µl (1mg/ml)volumeofa lipid (either DPPC
or DPPS) was carefully spread on the surface with a Hamilton
syringe, and the chloroform was allowed to evaporate before
starting the measurements. The film area is compressed with
two barriers, one on each side of the trough. The barriers are
coated with the polyacetal hydrophobic material “Delran” to
prevent the monolayer from sliding under the barriers and can
be driven symmetrically along the long side of the trough by a
motor that is controlled by a computer. The barrier speed
during compression was monitored at 5 mm/min and with the
subphase thermostated at 37 °C in the dark. For more details,
see [9].
Blood
Blood was collected at the blood bank, Haukeland
University Hospital, Bergen, anticoagulated with acid
citrate dextrose (“ACD”,8 5m MN a 3citrate, 71 mM citric
acid, 111 mM dextrose; 1 volume + 4 volumes of blood)
from regular blood donors and hemochromatosis patients
who claimed not to have taken any medications 10 days
prior to blood donation. We used blood from this patient
group as this blood is abundantly available to us after
therapeutic phlebotomy. Platelets from these two groups of
donors are the same with respect to all thrombin-induced
shape change, aggregation, secretion of ATP + ADP, PPI
metabolism, MLC phosphorylation, and PLA2 metabolism
in resting and thrombin-stimulated cells (unpublished
results). We have not found any literature reports which
J Chem Biol (2009) 2:89–103 91are to the contrary. In the experiments reported here, both
categories of platelets were used interchangeably.
AA-labeled, gel-filtered platelets
Concentrated platelet-rich plasma (PRP) was prepared from
the blood as described elsewhere [53, 70] and incubated
with 2.5 µCi [
3H]AA/ml PRP at 37 °C for 2 h and then
transferred by gel-filtration into a calcium-free Tyrode’s
solution, containing 0.2% bovine albumin and 5 mM
glucose. The process involves passing the PRP through a
column of Sepharose 2B with Tyrode solution at room
temperature; the platelets are excluded from the gel
particles and elute free of plasma immediately after the
void volume. The platelet count in radioactive GFP was
adjusted to 3.5×10
8 cells/ml with the Tyrode solution, and
the cells were used immediately in the experiments.
Preparation of [
32P] Pi-labelled, GFP for study of MLC
phosphorylation
Concentrated PRP was prepared from the blood as described
elsewhere[71] and incubated with 0.2 mCi [
32P ] P i / m la t3 7° C
for 1 h and then transferred by gel-filtration into calcium and
phosphate-free Tyrode’s solution but containing 0.1% bovine
albumin and 5 mM glucose as described in detail elsewhere
[44]. The platelet count in the radioactive GFP was adjusted
to 3.5×10
8 cells/ml, and the GFP was immediately used in
the experiments.
Preparation of [
32P] orthophosphate-labeled, gel-filtered
platelets (GFP) for study of the PPI cycle
This procedure was the same for the preparation of gel-
filtered platelets (GFP) for MLC phosphorylation, except that
the amount of radioactive orthophosphate was 0.1 mCi/ml,
and the serum bovine albumin concentration was 0.2%.
It should be noted that the Tyrode solutions used for
preparation of GFP for the experiments with MLC
phosphorylation and PPI cycle are different. For MLC
phosphorylation, we used less albumin (0.1%) than for the
PPI experiments (0.2 %) in order to avoid disturbance of
protein electrophoresis by the high albumin content. Both
solutions were free of [
31P] phosphate in order to prevent
dilution of the incorporated [
32P] by [
31P].
Incubation with drugs/controls and thrombin
Aliquots (in duplicate) of 500 µl of the [
32P]Pi-labelled
GFP were pre-equilibrated at 37 °C for 1 min, then 50 µl of
drug solution (30 µM final concentration) or 0.15 M NaCl
(control) was added, followed 90 s later by 50 µl of
thrombin at final concentrations of 0.0, 0.03, 0.05, 0.08,
0.1, and 0.3 U/ml. These mixtures were incubated at 37 °C
for another 90 s, and 500 µl aliquots of these mixtures were
transferred separately to extraction tubes containing 2 ml of
ice-cold chloroform/methanol/HCl (ratio 40:20:1), followed
by phase separation. The chloroform phases were evapo-
rated as described elsewhere [29]. The dried lipid extract
was dissolved in 40 µl chloroform, applied onto a silica thin-
layer plate (Silicagel 60, Aluminum, Merck, Darmstadt,
Germany) and chromatographed for 90 min with chloro-
form/methanol/20% methylamine in water (ratio 60:36:10) at
room temperature [71] .The radioactive spots were detected
and quantified with a Packard Instant Imager (Meriden, CT,
USA).
PPI cycle, a short summary
This cycle is one of the important metabolic pathways in
mammalian cells including those of the brain and human
platelets. The cycle starts with the phosphorylation of the 4-
hydroxy group of phosphatidylinositol (PI) by ATP catalyzed
by PI 4-kinase and forming phosphatidyl-4-phosphate (PIP).
This phosphate, however, is split off by a phosphohydrolase.
PIP is in turn phosphorylated in the 5-position by ATP, thus
forming phosphatidylinositol-4,5-bisphosphate (PIP2), and
this 5-phosphate is also split off by a phosphohydrolase.
Thus, both PIP and PIP2 exist in the cell as typical steady-
state levels and their monoester phosphate groups have high
turnover. This cycle turns over slowly in non-stimulated
platelets. However, it increases tremendously when the
platelets are activated with an agonist-like thrombin. This
cycle is explained in more detail elsewhere [53].
Expression of data
The Instant Imager expresses the relative radioactivity as
pixels. The pixel values for PIP2, PIP, and PA in the control
sample, that is, GFP incubated without addition of thrombin
or drug (NaCl-control), were set to 100, and the pixel
values in the same metabolites in the GFP samples
incubated with thrombin with or without drugs were
expressed relative to this value.
Thrombin-induced activation of PLA2
Portions of 500 µl of [
3H] AA-labelled GFP were pre-
incubated at 37 °C for 60 s. Then, 50 µl of solvents or
different drug solutions were added to the separate portions,
and incubation continued for a further 120 s, and after
addition of 50 µl of thrombin (0.27 U/ml final concentra-
tion), incubation proceeded for a further 6 min. Aliquots
(500 µl) of the incubation mixtures were added to 2 ml ice-
cold chloroform/methanol (ratio 2:1). Ice-cold chloroform
and water (500 µl of each) was then added, the mixture
92 J Chem Biol (2009) 2:89–103vortexed vigorously, and the samples were centrifuged at
50 rcf (5 min), so that phase separation was properly
achieved. The chloroform phases (containing extracted
lipids) were pipetted into separate Kimble tubes and
evaporated to dryness under a N2 jet as described elsewhere
[29]. The dried lipids were dissolved in 40 µl chloroform,
applied to silica thin-layer plates (Silicagel 60, Aluminum,
Merck, Darmstadt, Germany) and chromatographed for
90 min at room temperature with the upper phase of ethyl
acetate/iso-octane/glacial acetic acid/ddH2O (ratio
90:50:20:100). In this chromatography system, the phos-
pholipids remain at the application point, while free AA
had an Rf of 0.73. Small amounts of prostaglandins and
thromboxanes amounting to less than 0.6% of the total [
3H]
AA incorporated in the platelet phospholipids, were
produced, but these were ignored. The radioactive spots
were detected and quantified with a Raytest Radio-TLC
Analyzer (RITA-90, Raytek Scientific, Sheffield, England).
Thrombin-induced phosphorylation of 20-kDa myosin light
chain (MLC)
Portions of 500 µl [
32P]Pi-labeled GFP were pre-incubated at
37 °C with 50 µl of the drugs (30 µM, final concentration) or
their solvents (50 µl) for 90 s 50 µl of thrombin was added
(0.45 U/ml, final concentration) and the incubation continued
for another 6 min. To stop the reaction, 150 µl of the
incubation mixture was mixed with 75 µl 4× Laemmli
denaturing buffer [43]. The mixture was vortexed, sonicated
for 2 min, centrifuged at 15.300 rcf (3 min) and the
supernatants heated for 5 min at 95°C. The samples were
subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE; 12% separating gel; 4% stack-
ing gel) at 68 V, 500 mA (250 W) for 18 h at room
temperature, and the radioactive bands were visualized and
quantified using a Phosphoimager (Biorad).
Langmuir monolayer experiments:
The experiments were carried out with a KSV Minitrough
(Helsinki, Finland) with MilliQ water as the subphase and the
calculation of per cent change in mean molecular area at
surface pressures (Π) of10, 20, and 30 mN/m (normal surface
pressure at the cellular plasma membrane is between 20–
30 mN/m) for the drug-containing sample relative to that of
thecorrespondingareainthecontrolwithoutdrug,atthesame
surface pressures, was performed as described elsewhere [9].
Statistics
PLA2 and arachidonate liberation A mean value per donor
and drug was obtained by averaging the duplicates from
three experiments. Then, a two-tailed t test comparing the
means was conducted by comparing each of the values for
DZP, RSP, and ZIP to the control with DMSO. The same
approach was applied to PRZ and CTM by comparing them
to the control with NaCl. The control values were set to
100%, and the samples using drugs were normalized to
percent changes in comparison to the controls. The p values
(<0.05) obtained thus indicate if there was a statistically
significant change upon administration of the drug, com-
pared to the control.
Myosin light chain The respective control value [myosin
light chain (MLC) radioactivity in platelets not treated with
thrombin] for each donor was subtracted from the obtained
values (with thrombin) and the results obtained with DZP,
RSP, and ZIP were compared to the DMSO control by a two-
tailed t test comparing the means. The same approach was
applied to PRZ and CTM, and these were compared to the
NaCl control using the same two-tailed t test. The obtained p
values (<0.05) indicate whether there was a significant
difference between the drug-treated samples and the respec-
tive controls. Each drug was tested with platelets from three
different donors. Again, the mean control values were set to
100%, and the mean values for samples with drugs were
normalized to percent changes in comparison to the controls.
PPI cycle Descriptive statistics could not be used to
calculate p values because the data points on the drug curve
did not lie vertically over those of the control curve;
therefore, regression analysis was applied using polyno-
mials of second degree because we assumed that the
relationships between PA and PIP or PIP2 were expected
to be curved as we showed in detail in a previous paper.
This procedure allowed more logical treatment of curved
data because if the data were really linear, the second-
degree polynomial would be reduced to a linear polynomial.
For each drug, one pair of regression curves was con-
structed (one for control and the other drug-treated sample)
as described in Fig. 5. For details, see also Fig. 5 in [53].
Based on this analysis, a ranking order of means was made
to arrange the drugs according to their influence on PIP and
PIP2, and this is shown in rows 3 and 4 of Table 1,
respectively, where the highest-ranking number is a drug with
the highest impact on the tight control of PPI metabolites.
Results
Langmuir isotherms
Surface pressure versus mean molecular area (mma) curves
for DPPC and DPPS monolayers on distilled water at 37 °C
with or without PRZ, CTM, RSP, ZIP, or DZP in the
J Chem Biol (2009) 2:89–103 93subphase are shown in Fig. 1. Without any drugs, no
changes in surface pressure (Π) of the DPPC monolayer
(Fig. 1, left panels) took place as the mma decreased from
145 to 105 Å
2 showing that DPPC was in the gaseous
phase; a further decrease in mma, produced a sharp increase
in Π to about 30 mN/m at about 60 Å
2 at which point the
curve showed a small, but distinct, break point, and a
further decrease in mma produced an even sharper increase
in Π until the “collapse point” at 50 mN/m and 40 mma,
after which Π remained constant by further compression of
DPPC (One believes that the monolayer collapses by
folding over itself). During the sharp increase in Π between
105 mma (so-called “lift-off” point) and collapse point, the
glycerophospholipid is thought to go through the liquid to
solid state. For pure DPPS (Fig. 1, right panels), the Π/
mma isotherm resembled that of DPPC, except that lift-off
took place at about 50 Å
2, and the isotherm had no
breakpoint in the liquid-to-solid phases.
PRZ, CTM, RSP, and ZIP but not DZP, drastically
altered the DPPS isotherm (Fig. 1, right panels), but had
little effect on the DPPC isotherm (Fig. 1, left panels). It is
seen that in DPPS monolayers, PRZ, CTM, RSP, and ZIP at
1 µM concentration increased the mma at all Π levels and
also lowered the surface pressure at the collapse point. We
tested also the effects of 10 µM PRZ, CTM, RSP, ZIP, and
DZP on DPPC and DPPS monolayers under exactly the
same conditions as used in Fig. 1 and obtained very similar
results, i.e., hardly any effects on DPPC isotherms, apart
from PRZ which showed somewhat more effect than all the
four remaining drugs, and large increases in the mma at all
Π for DPPS except for DZP, which showed no increase in
mma at any Π. The increases (in percent) caused by 10 µM
of the drugs in mma at 10, 20, and 30 mN/m relative to the
corresponding Π in the control isotherms are presented in
Table 2. This table shows clearly that all five drugs have
little effect on the DPPC isotherm, while they markedly
increased the mma at 10, 20, and 30 mN/m of the PPS
isotherm, except DZP, which showed no increase.
Effects of psychotropic drugs on the liberation of [
3H] AA
from thrombin-stimulated human platelets
The comparison of the effects of all drugs on platelet PLA2
was measured by liberation of [
3H] AA after incubation for
6 min with thrombin (0.25 U/ml final concentration) using
platelets from three donors for each of all five drugs
(30 µM). The results are shown in Fig. 2.I ts h o u l db e
pointed out that since some of the drugs were only soluble in
DMSO, and the others in 0.15 M NaCl, two controls with
appropriate amounts of DMSO and 0.15 M NaCl, respec-
tively, were included. Black bars in Fig. 2 represent these
controls, and it can be seen that DMSO did not interfere with
thrombin-induced liberation of [
3H] AA. Fig. 2 clearly
shows that the thrombin-induced platelet PLA2 activation
was affected by these drugs. Except DZP, all other drugs
decreased PLA2 activation by 24–35% (relative to the
solvent controls); the decrease was significant for CTM
and RSP. The effect for DZP was the opposite in that it
actually increased PLA2 activity significantly (relative to
DMSO solvent control). The ranking order for decreased
PLA2 activation caused by these drugs was as follows:
ZIP > CTM   PRZ > RSP
Effects of the drugs on thrombin-induced phosphorylation
of the 20 kDa myosin light chain (MLC)
Because many phenothiazines are calmodulin inhibitors
[21], and the drug PRZ is also structurally a phenothiazine,
to find out whether PRZ and the other remaining four
psychotropic drugs also have such a property, we decided
to investigate the effects of these drugs on MLC phosphor-
ylation which is a calmodulin-dependent process in
thrombin-activated human platelets [12, 25].
[
32P] Pi-labeled GFP were incubated with or without
0.45 U/ml of thrombin in the presence of the drugs (30 μM)
Table 1 Relative differences and ranking order of the drugs’ interference with the tight coupling of PPI metabolites
Description PRZ CTM DZP ZIP RSP
1. Mean relative differences, mean (DPIP) 2.487 1.843 −0.022 0.071 −0.067
2. Mean relative differences, mean (DPIP2) −0.341 −0.091 −0.074 −0.617 −0.707
3. Ranking order for PIP 54132
4. Ranking order for PIP2 32145
5. p Values t test, H0: mean (DPIP)=0 0.000 0.000 0.638 0.728 0.85
6. p Values t test, H0: mean (DPIP2)=0 0.0392 0.6980 0.4457 0.0020 0.0010
7. Mean ranking order 4 3 1 3.5 3.5
The experiments exemplified with platelets from one donor, but different donor for each drug in Fig. 5. The experiments were repeated with
platelets from two more different donors for each drug. The data from altogether three donors for each drug were analyzed by regression using
polynomials of second degree, as explained in the “Materials and methods” section
94 J Chem Biol (2009) 2:89–103or their solvents for 6 min and the proteins separated by
SDS-PAGE. Fig. 3 shows an autoradiogram of a represen-
tative gel where it is evident that the 20 kDa band is not
labeled in the control platelets but became labeled on
incubation with thrombin without addition of the drugs.
The degree of labeling, however, was weaker in the
presence of ZIP and RSP, and almost not affected by PRZ
or DZP, while it increased in the presence of CTM. The
quantification of the labeling data is discussed below. Fig. 3
also shows that a band around 47 kDa that was not labeled
in control platelets became heavily labeled when the cells
were incubated with thrombin. This band represents
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Fig. 1 Effects of PRZ, CTP,
DZP, ZIP, and RSP/mean mo-
lecular area relations of DPPC
and DPPS monolayers. DPPC
and DPPS monolayers on pure
MilliQ water (straight line),
1µ M( dotted line) or10 µM
(dashed line) of the drugs (in
MilliQ water) were compressed
in the Langmuir apparatus at
37 °C and the surface pressure
measured with a Wilhelmy plate
as explained in [1, 9]. Three
experiments were performed for
each drug, and these gave iden-
tical results. The curves shown
in this figure are representative
for each group
J Chem Biol (2009) 2:89–103 95pleckstrin, a substrate for protein kinase C that is activated
by thrombin [12, 17]. Ziprasidone and RSP also reduced
the thrombin-induced labeling of Pleckstrin (Fig. 4).
The quantification of the level of 20 kDa MLC
phosphorylation from the type of experiment shown in
Fig. 3 is presented in Fig. 4. Evidently, CTM, PRZ, and
DZP stimulated or had no effect on MLC phosphorylation,
while ZIP and RSP reduced MLC phosphorylation by 6–
33%. The reduction with ZIP was significant.
Effects of psychotropic drugs on the tight control
of polyphosphoinositide metabolites in thrombin-stimulated
human platelets
The rate of PA formation in the PPI cycle in thrombin-
stimulated platelets was proportional to the thrombin
concentration up to the dose causing maximal stimulation
(0.3 U/ml). We have previously shown that changes in PIP
and PIP2 were proportional to the produced PA when
incubating the platelets with incremental increase in the
thrombin concentration [53]. In the present work, we
confirmed this observation. Since phenothiazines (neuro-
leptics) disturbed this tight coupling under similar con-
ditions [53, 72], we investigated these five carefully chosen
psychotropic drugs from three major different groups to
find out whether they disturb the tight metabolite coupling
using identical approaches as previously described [53]
with platelets from three different donors for each drug. The
drugs gave different patterns of change.
Regression analysis
The results of regression analysis with polynomials of
second degree of the raw data obtained from the experi-
ments with all five drugs are shown in Fig. 5. Prometha-
zine, CTM, and RSP show obvious increases in pixel
values for PIP, while DZP and RSP showed decreases when
compared to the control (without drugs; see row 1 in
Table 1). Concerning the changes in PIP2, all five drugs
without exception showed decreases in pixel values when
they were compared to the parallel controls (without drugs),
see row 2 in Table 1. The ranking order for PIP using the
five drugs (row 3, Table 1) was as follows;
PRZ > CTM > ZIP > RSP > DZP
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96 J Chem Biol (2009) 2:89–103On the other hand, the order for PIP2 (as seen in row 4,
Table 1) is;
RSP > ZIP > PRZ > CTM > DZP
The mean differences between the ranking orders for PIP
and PIP2 (see rows 3 and 4, Table 1) using the five drugs
are shown in row 7, Table 1 and are as follows;
PRZ > ZIP ¼ RSP > CTM > DZP
Discussion
In the present work, we have investigated how a sedative
DZP, an antihistaminic/hypnotic PRZ, two antipsychotics
(ZIP, RSP), and one antidepressive drug (CTM) interact with
phospholipid monolayers and affect glycerophospholipid-
hydrolyzing enzymes in human platelets, i.e., PLA2 and
control of the PPI cycle metabolites. Diazepam is a highly
lipophilic drug, while the remaining four are amphiphilic
ones (Scheme 1), and each of them, except DZP, increased
the mean molecular area of the acidic phospholipid DPPS,
while they had little effect on the monolayers of the neutral
phospholipid DPPC (Fig. 1, Table 2).
The greatest area-increasing effect on the DPPS mono-
layers was with PRZ and CTM, both of which are cationic
amphiphiles (Scheme 1), and they have the same effect on
DPPS monolayers as the phenothiazine drugs chlorproma-
zine (CPZ) [1] and trifluoperazine (TFP) [9, 67]. Solid-state
13C- and
31P-NMR studies of the interaction of CPZ and
porcine brain phosphatidyl serine (PBPS) bilayers have
clearly shown that the phenothiazine moiety is intercalated
between the acyl chains of PBPS, while the cationic tail
group is anchored electrostatically by the negatively
charged phosphate and carboxyl groups [73]. Promethazine
is also a phenothiazine derivative (Scheme 1) and is, like
CTM, most likely intercalated in the DPPS monolayer in
the same way as CPZ.
Unlike PRZ and CTM, the antipsychotics ZIP and RSP
gave only a modest area-increasing effect on the DPPS
monolayers, which may be explained by the virtual absence
of ionizable groups in these drugs (Scheme 1). Diazepam
has no ionizable group that may explain why it had no area-
increasing effect on the DPPS monolayers. According to
this discussion, we suggest the following “intercalation
ranking order” with decreasing intercalation ability for the
five drugs studied:
PRZ ¼ CTM > ZIP ¼ RSP > DZP ¼ 0 ðÞ
The main hypothesis that we have attempted to test
experimentally in this work, is if intercalation of a drug into
the platelet membrane occurs, then it should affect
phospholipid-requiring enzymatic processes. One such
process is the activation by thrombin of PLA2 measured
as liberation of free [
3H] AA from platelets prelabeled with
[
3H] AA. As shown in Fig. 2, the non-intercalating DZP
increased the production of [
3H] AA significantly, while
the intercalating drugs PRZ, CTM, ZIP, and RSP all
inhibited this process by 20–30%. There was, however, no
correlation between the degrees of inhibition of PLA2
(Fig. 2) and the percent increase in DPPS molecular area
(Table 2). We have previously demonstrated that 11 other
psychotropic drugs also inhibited thrombin-induced PLA2
Table 2 Per cent change in mean molecular area (mma) relative to
control (pure MilliQ water) at 10, 20, and 30 mN/m caused by 10 µM
PRZ, CTM, DZP, ZIP, RSP dissolved in MilliQ water
PC PS
Drug 20mN/m 10mN/m 20mN/m 30mN/m
PRZ 16.66 154.6 129.41 95.23
CTM 5.29 185.41 140.47 41.66
DZP 3.88 2.88 1.49 1.49
ZIP 4.70 39.84 24.67 10.67
RSP 4.76 28.06 10.10 3.15
The experiments were performed as described in the legend to Fig. 1,
and the percent change in mma at surface pressures of 10, 20, and
30 mN/m was calculated. Appropriate amounts of DMSO were
included in controls for DZP, ZIP, and RSP.
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Fig. 2 Comparison of the effects of all five drugs investigated on
thrombin- induced [
3H] arachidonate liberation in platelets. Gel-
filtered, [
3H] AA-labeled platelets were incubated with 0.25 U/ml of
thrombin at 37°C in the absence (black bars) or presence of drugs
(gray bars). After 90 s, the samples were extracted and processed as
described in the “Materials and methods” section. The free [
3H] AA
produced is presented as percentage of a control containing no
thrombin or drugs (set to 100%). The experiment was repeated three
times, each time with platelets from a different donor (giving a sum of
three experiments). The error bars show SEM, and the asterisks denote
p<0.05 compared to controls (i.e., without drugs)
J Chem Biol (2009) 2:89–103 97in human platelets to highly varying degrees [54]. Neither
did this correlate with their area-increasing effects on DPPS
monolayers [54]. One reason for the lack of correlation
could be that our monolayer experiments were done with
ion-free Milli-Q water of about pH 6, while the experiments
with intact platelets were done in Tyrode’ss o l u t i o n
containing 140 mM Na
+ ions. This cation (and many
others) counteracts the monolayer area-increasing effect of
CPZ [1] and could well counteract the area-increasing
effects of PRZ, ZIP, RSP, and CTM that are cations at the
pH used. Nevertheless, the main purpose of our studies
with monolayers was to disclose any interactions between
the drugs and the phospholipids, and we therefore, on
purpose, selected conditions (i.e., MilliQ water in subphase)
that most sensitively would reveal such interactions.
Many phenothiazines are calmodulin antagonists [59],
and this property could be involved in the inhibition of
platelet PLA2 by the phenothiazine PRZ and possibly by
the other drugs studied here. In order to distinguish whether
or not calmodulin antagonism was involved, we have
measured the effect of the drugs on myosin light chain
phosphorylation, which, in human platelets, is dependent
on calmodulin [25] and activated by thrombin [12]i n
parallel with PLA2 [30]. As shown in Fig. 4, only ZIP
caused significant inhibition of myosin light chain phos-
phorylation, suggesting that calmodulin could be involved,
whereas the inhibition caused by PRZ, CTM, and RSP was
clearly calmodulin-independent.
In intact platelets, the drugs are exposed to membrane
bilayers where the acyl groups in one layer face acyls from
the opposite layer. In the monolayer experiments we have
performed, however, the acyl groups are facing air. Thus, in
bilayers the acyl groups of one layer may influence the
property of the phospholipids in the other layer. One
example for such a difference is that optimal intercalation
of CPZ in liposomes, which are bilayers, was optimal when
the mol% ratio of PC to PS was 2 [69], while intercalation
of TFP was directly proportional to the PS concentration in
monolayers of PS and PC [9]. Thus, the lack of correlation
between the inhibition of PLA2 by PRZ, CTM, RSP, and
ZIP, and the intercalation in DPPS monolayers in the
present work may be due to the bilayer/monolayer
difference.
The PPI cycle perturbance by psychotropic drugs has
been thoroughly discussed in a previous paper [53] where
we also showed that when the cycle is stimulated by
thrombin, there is a tight control of the levels of PA, PIP,
and PIP2; this tight coupling was markedly changed by six
antipsychotic drugs. Our group has found that the pheno-
thiazine antipsychotic CPZ also interferes with this control
[72]. It was the observation of this phenomenon which
actually led us to further investigate whether or not other
antipsychotics (typical and atypical) could have this
property as well. We found that this property is a common
feature of all the antipsychotics we investigated, yet it was
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Fig. 3 SDS-PAGE of [
32P] Pi-labeled, gel-filtered platelets treated
with thrombin in the absence or presence of drugs. Aliquots (500 µl) of
[
32P]Pi-labeled, gel-filtered platelets were incubated with 50 µl of the
drugs (30 µM, final concentration) or their solvents for 90 s at 37 °C,
then 50 µl thrombin (0.45 U/ml, final concentration) or NaCl (0.15 M)
were added to the samples, and incubation continued for another
6 min, then 150 µl of incubation mixture was immediately mixed with
75 µl 4× Laemli buffer as described in the “Materials and methods”
section (thrombin-induced phosphorylation of 20-KDa MLC)
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Fig. 4 Effects of all five drugs on thrombin-induced myosin light
chain phosphorylation. Myosin light chain in unstimulated samples
(controls) is set to 100%, and the other values were normalized to
percent of the controls. These data were obtained from the sum of
three different experiments each with platelets from a different donor.
See legend to Fig. 3 for experimental details. The error bars (in gray)
show SEM values in samples with drugs, and the asterisk denotes p<
0.05 compared to the myosin light chain phosphorylation in the
controls (i.e., black bars are without drugs)
98 J Chem Biol (2009) 2:89–103different from one drug to another (concerning both the
pattern and intensity) [53]. In the present work, we have
investigated the effects of five different psychotropic drugs
(from three different groups) on the PPI cycle. Again, we
confirmed that these drugs, apart from DZP, interfere with
inositol phospholipid metabolism (see Fig. 5).
Promethazine gave a pattern similar to the other
phenothiazines, in that it increased PIP and decreased
PIP2 levels. The decrease in PIP2 level was not pronounced
as we encountered with the other three phenothiazines, i.e.,
CPZ, TFP, and PCP [53, 72].
The difference with this phenothiazine is that it is not
used as an antipsychotic drug; as a matter of fact, it is used
clinically as an antihistaminic in order to treat allergy/
pruritis and induce hypnosis [11, 61], so it would be
expected to have a different interference potency on PPI
metabolism than antipsychotic–phenothiazines. The de-
crease in PLA2 activity caused by PRZ was not significant
compared to other phenothiazines [54]. It is also important
to emphasize that PRZ (in contradiction to other pheno-
thiazines) did not cause any decrease in MLC phosphory-
lation, that is to say, it did not antagonize calmodulin [54].
Citalopram, the SSRI antidepressant, disturbed the tight
coupling of PPI cycle metabolites, as it increased the levels
of PIP by approximately 60% over control levels, but it
increased the PIP2 levels negligibly. It also decreased AA
liberation (via inhibiting PLA2) significantly, similar to
other antidepressants [54]. It caused a 6% increase in MLC
phosphorylation in contrast to the tricyclic antidepressants
which decreased MLC phosphorylation [54] more potently.
The two atypical antipsychotic drugs, RSP and ZIP,
showed similar patterns concerning disturbance of PPI
metabolism, in that both decreased PIP and PIP2 levels but
in different potencies. This finding is quite different from
the effects of other drugs investigated by our group up to
now. In our previous study [53], all antipsychotic drugs
tested caused an increase in PIP levels. This might give us
important information about the different modes of action
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Fig. 5 Effects of PRZ, CTP,
DZP, ZIP, and RSP (30 µM) on
the tight coupling of PPI cycle
metabolites in platelets .The data
analyzed by regression. The data
shown here are from experi-
ments with platelets from one
donor, but there was a different
donor for each drug. Each ex-
periment was repeated twice for
each drug with platelets from
two different donors. These
gave an identical pattern of
results. The data were analyzed
by regression using polynomials
of second degree as explained in
the “Statistics” section and
shown in Table 1. The controls
(without drugs) are shown as
circles connected with solid
lines, the samples with drugs are
depicted as crosses connected
with broken lines
J Chem Biol (2009) 2:89–103 99of these relatively new preparations. These two drugs are
atypical antipsychotics; they have lower therapeutic doses
than phenothiazine-derived antipsychotics; for example, the
daily therapeutic dose for RSP is 2–16 mg, which is much
less than the daily dose of CPZ which is 100–1,500 mg [7].
Risperidone and ZIP, similar to other antipsychotic prepa-
rations, decreased (PLA2 dependent) AA liberation; ZIP
was more potent than RSP, but the decrease caused by RSP
was statistically significant. Both of these two drugs
decreased MLC phosphorylation, ZIP caused a more potent
and significant decrease.
In the present study, DZP was different from all other
drugs we have investigated up to now. It showed negligible,
almost undetectable changes, in the levels of PIP and PIP2
in comparison to control values. Table 1 shows that the
ranking order for changes in PIP as 1 and for PIP2 again as
1, which makes the mean ranking order for interference
(change) as 1 in comparison to the effects of the other four
drugs on their corresponding control samples. Diazepam
did not cause any increase in mma neither with DPPC nor
with DPPS, meaning that the drug has no ability to bind
phospholipid monolayers. It did not decrease AA liberation
like the other drugs, but actually resulted in an increase of
almost 20% compared to control values (normalized to
100%).
In the literature, there are indications that DZP antago-
nizes calmodulin [6, 40] in mammalian cells other than
human platelets. But in our experiments, which have been
repeated nine times from platelets obtained from nine
different donors, we did not see any decrease in MLC
phosphorylation in comparison to the control sample. This
finding also proves that the drug is not intercalating
between the membrane phospholipids in contrast to TFP,
for example [29, 30]. We can therefore explain why DZP
does not interfere negatively with these three biological
phenomena (PPI cycle, PLA2, and MLC phosphorylation)
in human platelets. Intercalation into membrane phospho-
lipids disturbs the substrate availability of membrane-
associated phospholipases like PLC and PLA2 [8]. It is
thus evident that DZP must induce its pharmacological
actions through other mechanisms in human platelets (as in
this work), as well as other types of mammalian cells
including neurons. It is well known, and thoroughly
documented, that DZP exerts its effects through binding
to BDRs [14, 23, 47, 48, 66], so the drug binds to the
peripheral BDRs, which are scattered in platelet membrane
phospholipids, and in mitochondrial membrane phospholi-
pids where they regulate steroid metabolism [23, 66].
Furthermore, they mediate inhibition of mitochondrial
respiratory control so that they decrease metabolic rate
[27, 51] and may contribute to the action of the central
BDR (in neurons) to induce hypnosis and/or terminate an
epileptic fit (when administered intravenously) with the
anticonvulsant drug DZP [58]. Diazepam is a very
lipophilic unionizable drug [16, 50] [see also Scheme 1],
and this property enables the molecule to permeate readily
through membrane phospholipids as this process is ther-
modynamically favorable and not energy demanding.
Therefore, it crosses the blood–brain barrier easily similar
to other addictive unionizable agents like heroin and
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100 J Chem Biol (2009) 2:89–103cocaine [19]. Diazepam and other benzodiazepines are
addictive drugs when they are used continuously for more
than 14 days [49]. Taking into account available data in the
literature and the results of the present work, we can
understand why DZP exerts its effects via a receptor-
dependent mechanism in contrast to the other four
amphiphilic psychotropic drugs (PRZ, CTM, ZIP, and
RSP). These four drugs intercalate into the membrane
phospholipid bilayer in such a way that they change the
alignment of distinct receptors, thus modifying their
availability for agonists. In so doing, they alter the substrate
availability for the enzymes catalyzing many metabolic
processes [8].
When reviewing the results obtained concerning the
stimulatory action of DZP on cPLA2, we can predict that
this drug may deteriorate the clinical picture of psychosis
and depression, besides, within conventional therapeutic
doses, DZP as a sole preparation is not a first line agent in
drug treatment of neither psychosis [46] nor depression. In
the work described here and that reported by [54], we have
shown that this drug opposes the action of all antipsychotic
and antidepressant drugs tested because all these drugs
(antipsychotics and antidepressives) decrease the rate of
membrane phospholipid turnover by inhibiting the catalytic
action of cPLA2. We have to admit, however, that up to
today, there exists no clinical proof to back our claim. In
contrast, benzodiazapines are still in use especially in
combination with antipsychotic drugs [10, 56], and their
use is still highly recommended, especially in catatonic
schizophrenia, where agitation, restlessness, and stupor are
cardinal symptoms besides psychosis [26, 32]. Diazepam
should not be recommended for long-term applications,
taking into consideration the hazards of abstinence and
addiction which are actually disadvantages for DZP and all
benzodiazepines. In other words, one can switch to other
hypnotic/sedative drugs as an alternative, like Zopiclone
which is more beneficial than DZP to induce hypnosis [35,
36] and to treat negative symptoms of chronic schizophren-
ic patients [39]. There is evidence indicating that Zopiclone
is less risky than benzodiazepine preparations with respect
to the induction of addiction [33, 76].
Since human platelets possess D2-like receptors [60], it
is possible that the action of psychotropic drugs on the PPI
cycle and PLA2 are mediated through antagonizing these
receptors. However, due to our results from the monolayer
experiments, these drugs except DZP may also induce their
effects at the cellular level by modifying different receptors
through intercalation in the inner leaflet of acidic membrane
phospholipids. The drugs have been incubated with the
platelets at 30 µM, a concentration that is considerably
higher than in plasma during therapy. However, during
therapy, multiple doses of drugs are administered therapeu-
tically, and the drugs need to be available for days or even
w e e k si no r d e rf o rt h e mt ob ea b l et oi n d u c et h e i r
therapeutic pharmacological action. This is because most
drugs have to accumulate to certain levels before a response
is exerted. The drugs used in the present work are either
amphiphilic or lipophilic; they accumulate in cellular
membranes. Therefore, we believe that use of 30 µM drug
for 90 s may indeed be comparable to the in vivo situation
In conclusion, the work presented here gives us valuable
new information with regard to the possibility of designing
new and more effective drugs than those presently available
for treatment of psychiatric morbidities, a current major
medical problem in western society. The aim is to develop
new drugs that have no undesirable side effects and do not
cause problems of addiction.
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